MedTrace Logo

A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors

NCT00404521 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2014-03-26

No results posted yet for this study

Summary

Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study. The purpose is to determine the safety, tolerability and to identify the dose limiting toxicities(DLT) and recommended dose (RD) of PM02734 administered every 3 weeks, intravenously, over 30 minutes to subjects with advanced malignant solid tumors.

Conditions

Interventions

DRUG

PM02734

Administered every 3 weeks, intravenously, over 30 minutes

Sponsors & Collaborators

  • PharmaMar

    lead INDUSTRY

Principal Investigators

  • Mark Ratain, MD · Cancer Research Centerr, University of Chicago Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00404521 on ClinicalTrials.gov